Immunoglobulin E specific for Atriplex canescens pollen proteins (IgE (Atriplex canescens))

Immunoglobulin E (IgE) antibodies specific for Atriplex canescens (Fourwing saltbush) pollen proteins are the primary mediators of allergic reactions to this plant, which is a significant source of aeroallergens in arid and semi-arid regions. These antibodies are produced by B cells upon sensitization to specific saltbush allergens, such as the profilin Atr c 1. When an individual is re-exposed to the pollen, the allergens cross-link the specific IgE molecules bound to high-affinity FcεRI receptors on the surface of mast cells and basophils. This cross-linking triggers the immediate release of inflammatory mediators, including histamine, leukotrienes, and cytokines, which result in clinical symptoms of allergic rhinitis, conjunctivitis, and bronchial asthma. In the context of drug development and therapy, these specific IgE antibodies are targeted indirectly by anti-IgE monoclonal antibodies like omalizumab, which bind to the Fc region of free IgE to prevent receptor binding, or addressed through allergen-specific immunotherapy (AIT) designed to shift the immune response toward tolerance.

Other names

Anti-Atriplex canescens IgESaltbush-specific IgEFourwing saltbush IgEsIgE to Atriplex canescens

Binding to the Cε3 domain of free IgE to prevent its interaction with the high-affinity IgE receptor (FcεRI) on mast cells and basophils, thereby inhibiting the allergic cascade.